Search Results 1251-1260 of 13926 for Assay

  1. A Trial Of The FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant For Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) - Mayo Clinic

    Participant has active hepatitis B infection as determined by NAAT or surface antigen assay. Participants who have acquired immunity from past exposure ...

  2. Ductal Carcinoma In Situ Clinical Trials - Mayo Clinic Research

    GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study ...

  3. Primary aldosteronism: The role of adrenal venous sampling - Mayo Clinic

    All of the blood samples should be assayed ... Accurate laboratory assays for cortisol and aldosterone are keys to successful interpretation of the AVS data.

  4. Ductal Carcinoma In Situ (DCIS) Clinical Trials - Mayo Clinic Research

    GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study ...

  5. Advanced Endocrinology Fellowship (Minnesota) - Residencies and Fellowships - Mayo Clinic College of Medicine & Science

    Clinical Laboratory Medicine (pertaining to thyroid assays as organized by clinical lab medicine consultants); Nuclear medicine (iodine WBS, PET scan ...

  6. A Study to Evaluate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer - Mayo Clinic

    Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration. Study entry PSA should not be ...

  7. Dementia Clinical Trials - Mayo Clinic Research

    Blinded Comparison of Different Alpha-Synuclein Seeding Assays as ... assay measures of aSyn, relative to normal control subjects. Specific Aim 2.

  8. Efficacy And Safety Of Treatment With Alpelisib Plus Endocrine Therapy In Patients With HR+, HER2-negative ABC, With PIK3CA Mutations, Whose Disease Has Progressed On Or After CDK 4/6 Treatment With An Aromatase Inhibitor (AI) Or Fulvestrant - Mayo Clinic

    Patient has a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (either from tissue or blood).

  9. Diarrhea Clinical Trials - Mayo Clinic Research

    The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam. A Study of ...

  10. HeadStart4: Newly Diagnosed Children (<10 Y/o) With Medulloblastoma And Other CNS Embryonal Tumors - Mayo Clinic

    ... assays: all stages, age less than 6 years at diagnosis. Posterior fossa classic or anaplastic/large cell medulloblastoma with sufficient tumor material ...